Last reviewed · How we verify
Combination Medication Treatment Group
A combination medication treatment approach that uses multiple drugs together to enhance therapeutic efficacy through synergistic mechanisms.
At a glance
| Generic name | Combination Medication Treatment Group |
|---|---|
| Sponsor | Cedars-Sinai Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This represents a treatment strategy rather than a single drug entity, combining multiple pharmaceutical agents to target disease pathways simultaneously or sequentially. The specific mechanism depends on the individual drugs included in the combination regimen.
Approved indications
Common side effects
Key clinical trials
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (PHASE2)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
- Early vs Delayed Intravesical Blad-Care During BCG Therapy (NA)
- Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: